Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Trump dishes on Milley clash over leaving military...
TikToker knocks Harris’ ‘weird’ take on never released...
‘Who wouldn’t want it?’: Netanyahu open to receiving...
Supreme Court lets Trump’s ‘wrecking ball’ federal job...
Biden’s strange use of teleprompter in donor’s home...
Tariff case pits Cato Institute against Trump over...
GREGG JARRETT: CIA report makes it clear Trump...
State Department investigating Rubio AI impersonator who contacted...
DOJ lands legal victory as federal judge allows...
Senate Republican moves to give US an edge...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Investing

Cardiex September 2024 Quarter Update

by admin October 31, 2024
October 31, 2024
Cardiex September 2024 Quarter Update

Cardiex Limited (ASX:CDX) (the “Company”) is pleased to report its activities during the September quarter 2024.

Highlights:

  • Manufacturing of the initial 8,000 CONNEQT Pulse units commenced with the expected arrival of units in the USA late-November/early December.
  • Pulse waitlist now exceeds 20,000 with activities now focused on sales conversion.
  • Completed clinical validation study of wearable technology, with an FDA pre-submission meeting scheduled for November to advance the clearance process.
  • Completion of usability study for submission for additional OTC clearance for the Pulse.
  • Strong clinical sales pipeline with momentum towards new Q2 contracts.
  • Grand prize winner of the U.S. National Institute of Health’s RADx® Maternal Health Challenge securing US$525,000 in prize funding.
  • New R&D Term Loan Facility with Mitchell Asset Management to provide additional flexibility with R&D initiatives and working capital requirements.

Click here for the September Quarterly Appendix 4C

Click here for the full ASX Release

This post appeared first on investingnews.com

previous post
WGC: Gold Demand Hits Q3 Record as Western ETF Investors Return
next post
Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

You may also like

Successful Completion of Tranche 1 Share Placement

November 8, 2024

Nimbus Zinc Silver Project Update

September 2, 2024

Silver Reserves: Top 5 Countries

May 29, 2025

Argentina Lithium and Energy Exhibiting at Booth 2924,...

February 27, 2025

Shallow, high-grade gold in Sandstone drilling

April 10, 2025

Crypto Market Recap: $TRUMP Token Soars as President...

April 27, 2025

Forte Minerals Announces Private Placement of up to...

May 24, 2025

Japanese testwork achieves top results

February 17, 2025

Crypto Market Recap: Strategy Eyes US$1 Billion Capital...

June 7, 2025

What is the Gold Spot Price? (Updated 2024)

September 11, 2024

Recent Posts

  • Trump dishes on Milley clash over leaving military equipment in Afghanistan: ‘I knew he was an idiot’
  • TikToker knocks Harris’ ‘weird’ take on never released interview: ‘Not good’
  • ‘Who wouldn’t want it?’: Netanyahu open to receiving stealth bombers, bunker-busters from US
  • Supreme Court lets Trump’s ‘wrecking ball’ federal job cuts proceed while legal fight continues
  • Biden’s strange use of teleprompter in donor’s home infuriated supporters, dashed expectations

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (818)
    • Investing (2,487)
    • Politics (3,085)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.